Showing 8731-8740 of 18119 results for "".
- Innovation in Pancreatic Cancer Care: UT Health San Antonio's Breakthrough with Radiofrequency Ablationhttps://reachmd.com/news/innovation-in-pancreatic-cancer-care-ut-health-san-antonios-breakthrough-with-radiofrequency-ablation/2484938/UT Health San Antonio performed the first regional endoscopic radiofrequency ablation (RFA) for an inoperable pancreatic cancer pat
- Evaluating Nerinetide in Acute Ischemic Stroke: Insights from Latest Meta-Analysishttps://reachmd.com/news/evaluating-nerinetide-in-acute-ischemic-stroke-insights-from-latest-meta-analysis/2484951/Nerinetide, delivered intravenously as a neuroprotective adjunct during endovascular thrombectomy (EVT) when IV thrombolysis is withheld, does not improve 90‑day functional outcomes.
- Isotretinoin Slows Growth Rate in Teens, But Final Height Unchangedhttps://reachmd.com/news/isotretinoin-slows-growth-rate-in-teens-but-final-height-unchanged/2484962/Adolescents treated with isotretinoin for acne may experience temporary reductions in height velocity, but the medication does not appear to impact final adult height, according to a new retrospective cohort study published in the
- Revolutionizing Renal Replacement: Impact of the FDA's Breakthrough Device Designation for Holly Implantable Kidneyhttps://reachmd.com/news/revolutionizing-renal-replacement-impact-of-the-fdas-breakthrough-device-designation-for-holly-implantable-kidney/2484940/Nephrodite’s Holly implantable kidney
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://reachmd.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to
- Evaluating Targeted Therapies for Inflammatory Skin Diseases: A Focus on Baricitinib in Lichen Planushttps://reachmd.com/news/evaluating-targeted-therapies-for-inflammatory-skin-diseases-a-focus-on-baricitinib-in-lichen-planus/2484952/Mayo Clinic investigators show that baricitinib produces rapid clinical benefit in liche
- Reframing MASLD: Oxygen-Nutrient Imbalance as a Key Driver of Diseasehttps://reachmd.com/news/masld-oxygen-nutrient-imbalance/2484916/In a new review, researchers reframe metabolic dysfunction-associated steatotic liver disease (MASLD) as a supply-demand injury in which excess portal caloric delivery can outpace hepatic oxyge
- Neonatal Outcomes in Preterm Infants by Gestational Age: Insights from a Retrospective Cohort Studyhttps://reachmd.com/news/neonatal-outcomes-preterm-infants-gestational-age/2484917/A recent cohort study provides new data on short-term neonatal outcomes across late‑preterm, early‑term, and full‑term births, quantifying risks that inform timing of elective delivery.
- Regulatory Milestones for the Holly Implantable Dialysis System: A New Era in Renal Replacement Technologyhttps://reachmd.com/news/holly-implantable-dialysis-renal-replacement/2484925/The Holly implantable dialysis system has received FDA Breakthrough Device de
- Decoding Fetal Microcephaly: Genetic Insights from a Recent Prenatal Cohort Studyhttps://reachmd.com/news/fetal-microcephaly-genetic-prenatal-cohort/2484924/In a prenatal cohort, researchers found marked genotypic and phenotypic heterogeneity among fetuses with clinically identified microcephaly. In 197 fetuses referred fo